These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32114828)

  • 1. Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease.
    Augusto JB; Nordin S; Vijapurapu R; Baig S; Bulluck H; Castelletti S; Alfarih M; Knott K; Captur G; Kotecha T; Ramaswami U; Tchan M; Geberhiwot T; Fontana M; Steeds RP; Hughes D; Kozor R; Moon JC
    Circ Cardiovasc Imaging; 2020 Mar; 13(3):e010171. PubMed ID: 32114828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of base-to-apex circumferential strain gradient assessed by cardiovascular magnetic resonance in Fabry disease: relationship to T1 mapping, late gadolinium enhancement and hypertrophy.
    Mathur S; Dreisbach JG; Karur GR; Iwanochko RM; Morel CF; Wasim S; Nguyen ET; Wintersperger BJ; Hanneman K
    J Cardiovasc Magn Reson; 2019 Aug; 21(1):45. PubMed ID: 31366357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage.
    Augusto JB; Johner N; Shah D; Nordin S; Knott KD; Rosmini S; Lau C; Alfarih M; Hughes R; Seraphim A; Vijapurapu R; Bhuva A; Lin L; Ojrzyńska N; Geberhiwot T; Captur G; Ramaswami U; Steeds RP; Kozor R; Hughes D; Moon JC; Namdar M
    Eur Heart J Cardiovasc Imaging; 2021 Jun; 22(7):790-799. PubMed ID: 32514567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy.
    Nordin S; Kozor R; Vijapurapu R; Augusto JB; Knott KD; Captur G; Treibel TA; Ramaswami U; Tchan M; Geberhiwot T; Steeds RP; Hughes DA; Moon JC
    Circ Cardiovasc Imaging; 2019 Dec; 12(12):e009430. PubMed ID: 31826677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global longitudinal strain, myocardial storage and hypertrophy in Fabry disease.
    Vijapurapu R; Nordin S; Baig S; Liu B; Rosmini S; Augusto J; Tchan M; Hughes DA; Geberhiwot T; Moon JC; Steeds RP; Kozor R
    Heart; 2019 Mar; 105(6):470-476. PubMed ID: 30282640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proposed Stages of Myocardial Phenotype Development in Fabry Disease.
    Nordin S; Kozor R; Medina-Menacho K; Abdel-Gadir A; Baig S; Sado DM; Lobascio I; Murphy E; Lachmann RH; Mehta A; Edwards NC; Ramaswami U; Steeds RP; Hughes D; Moon JC
    JACC Cardiovasc Imaging; 2019 Aug; 12(8 Pt 2):1673-1683. PubMed ID: 29778854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Clinical Evolution in Prehypertrophic Fabry Disease.
    Camporeale A; Pieroni M; Pieruzzi F; Lusardi P; Pica S; Spada M; Mignani R; Burlina A; Bandera F; Guazzi M; Graziani F; Crea F; Greiser A; Boveri S; Ambrogi F; Lombardi M
    Circ Cardiovasc Imaging; 2019 Apr; 12(4):e008424. PubMed ID: 30943767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance.
    Pica S; Sado DM; Maestrini V; Fontana M; White SK; Treibel T; Captur G; Anderson S; Piechnik SK; Robson MD; Lachmann RH; Murphy E; Mehta A; Hughes D; Kellman P; Elliott PM; Herrey AS; Moon JC
    J Cardiovasc Magn Reson; 2014 Dec; 16(1):99. PubMed ID: 25475749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular hypertrophy: do not forget Fabry disease. Diagnostic work-up and differential diagnosis.
    Paelinck BP; Bondue A; Robyns T; Eyskens F
    Acta Cardiol; 2024 Aug; 79(6):642-649. PubMed ID: 38869089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study.
    Weidemann F; Beer M; Kralewski M; Siwy J; Kampmann C
    Mol Genet Metab; 2019 Feb; 126(2):169-182. PubMed ID: 30594474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac Phenotype of Prehypertrophic Fabry Disease.
    Nordin S; Kozor R; Baig S; Abdel-Gadir A; Medina-Menacho K; Rosmini S; Captur G; Tchan M; Geberhiwot T; Murphy E; Lachmann R; Ramaswami U; Edwards NC; Hughes D; Steeds RP; Moon JC
    Circ Cardiovasc Imaging; 2018 Jun; 11(6):e007168. PubMed ID: 29853467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Fabry Disease cardiac involvement according to longitudinal strain, cardiometabolic exercise test, and T1 mapping.
    Réant P; Testet E; Reynaud A; Bourque C; Michaud M; Rooryck C; Goizet C; Lacombe D; de-Précigout V; Peyrou J; Cochet H; Lafitte S
    Int J Cardiovasc Imaging; 2020 Jul; 36(7):1333-1342. PubMed ID: 32385539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of left atrial size and function in hypertrophic cardiomyopathy and in Fabry disease with left ventricular hypertrophy.
    Saccheri MC; Cianciulli TF; Challapa Licidio W; Lax JA; Beck MA; Morita LA; Gagliardi JA;
    Echocardiography; 2018 May; 35(5):643-650. PubMed ID: 29457264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-wave inversions related to left ventricular basal hypertrophy and myocardial fibrosis in non-apical hypertrophic cardiomyopathy: a cardiovascular magnetic resonance imaging study.
    Chen X; Zhao S; Zhao T; Lu M; Yin G; Jiang S; Prasad S
    Eur J Radiol; 2014 Feb; 83(2):297-302. PubMed ID: 24332848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping.
    Sado DM; White SK; Piechnik SK; Banypersad SM; Treibel T; Captur G; Fontana M; Maestrini V; Flett AS; Robson MD; Lachmann RH; Murphy E; Mehta A; Hughes D; Neubauer S; Elliott PM; Moon JC
    Circ Cardiovasc Imaging; 2013 May; 6(3):392-8. PubMed ID: 23564562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance.
    Ferreira VM; Piechnik SK; Dall'Armellina E; Karamitsos TD; Francis JM; Choudhury RP; Friedrich MG; Robson MD; Neubauer S
    J Cardiovasc Magn Reson; 2012 Jun; 14(1):42. PubMed ID: 22720998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute impact of an endurance race on cardiac function and biomarkers of myocardial injury in triathletes with and without myocardial fibrosis.
    Tahir E; Scherz B; Starekova J; Muellerleile K; Fischer R; Schoennagel B; Warncke M; Stehning C; Cavus E; Bohnen S; Radunski UK; Blankenberg S; Simon P; Pressler A; Adam G; Patten M; Lund GK
    Eur J Prev Cardiol; 2020 Jan; 27(1):94-104. PubMed ID: 31242053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial lipid content in Fabry disease: a combined
    Petritsch B; Köstler H; Weng AM; Horn M; Gassenmaier T; Kunz AS; Weidemann F; Wanner C; Bley TA; Beer M
    BMC Cardiovasc Disord; 2016 Oct; 16(1):205. PubMed ID: 27793097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation between Fabry disease and hypertrophic cardiomyopathy with cardiac T1 mapping.
    Deborde E; Dubourg B; Bejar S; Brehin AC; Normant S; Michelin P; Dacher JN
    Diagn Interv Imaging; 2020 Feb; 101(2):59-67. PubMed ID: 31519470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Myocardial Perfusion in Fabry Disease.
    Knott KD; Augusto JB; Nordin S; Kozor R; Camaioni C; Xue H; Hughes RK; Manisty C; Brown LAE; Kellman P; Ramaswami U; Hughes D; Plein S; Moon JC
    Circ Cardiovasc Imaging; 2019 Jul; 12(7):e008872. PubMed ID: 31269811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.